As a Condition of Acquiring Meda, FTC Requires Mylan to Divest Rights to Two Generic Drugs, One for Muscle Spasms and Stiffness, the other for Epilepsy
Date
Mylan Inc. has agreed to divest the rights and assets related to two generic pharmaceutical products in order to settle FTC charges that its proposed $7.2 billion acquisition of Swedish drug maker...